SG10201501496TA - Cancer diagnosis and imaging - Google Patents
Cancer diagnosis and imagingInfo
- Publication number
- SG10201501496TA SG10201501496TA SG10201501496TA SG10201501496TA SG10201501496TA SG 10201501496T A SG10201501496T A SG 10201501496TA SG 10201501496T A SG10201501496T A SG 10201501496TA SG 10201501496T A SG10201501496T A SG 10201501496TA SG 10201501496T A SG10201501496T A SG 10201501496TA
- Authority
- SG
- Singapore
- Prior art keywords
- imaging
- cancer diagnosis
- diagnosis
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 238000003384 imaging method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H30/00—ICT specially adapted for the handling or processing of medical images
- G16H30/20—ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30903010P | 2010-03-01 | 2010-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201501496TA true SG10201501496TA (en) | 2015-04-29 |
Family
ID=44542787
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201501496TA SG10201501496TA (en) | 2010-03-01 | 2011-02-28 | Cancer diagnosis and imaging |
| SG2012055232A SG183114A1 (en) | 2010-03-01 | 2011-02-28 | Cancer diagnosis and imaging |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012055232A SG183114A1 (en) | 2010-03-01 | 2011-02-28 | Cancer diagnosis and imaging |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9427429B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2542155B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6017964B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101821343B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102781316B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011223883B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2787673A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2557407T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL221035A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX360640B (cg-RX-API-DMAC7.html) |
| SG (2) | SG10201501496TA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011109262A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201205377B (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4927735B2 (ja) * | 2004-08-20 | 2012-05-09 | ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン | Ｔ型カルシウムチャネル阻害剤 |
| AU2011223883B2 (en) | 2010-03-01 | 2015-10-08 | Cavion, Inc. | Cancer diagnosis and imaging |
| EA039877B1 (ru) * | 2016-07-19 | 2022-03-23 | Бристол-Майерс Сквибб Компани | Радиолиганды для визуализации фермента ido1 |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| KR102642063B1 (ko) | 2017-02-15 | 2024-03-04 | 카비온, 인코포레이티드 | 칼슘 채널 억제제 |
| AU2020231916B2 (en) | 2019-03-01 | 2025-08-28 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1219609A (en) | 1968-07-19 | 1971-01-20 | Koninklijke Pharma Fab Nv | Diphenylmethoxyethylamino derivatives |
| US3732247A (en) | 1970-08-14 | 1973-05-08 | Robins Co Inc A H | 3-di-substituted methylene pyrrolidines wherein the 1-or n-lower-alkyl substituent contains at least two carbon atoms |
| US4091103A (en) | 1976-06-23 | 1978-05-23 | Ciba-Geigy Corporation | Quinolyl or isoquinolyl-lower-alkoxy-phenylene-amino derivatives |
| JPS59161392A (ja) | 1983-03-04 | 1984-09-12 | Nippon Shinyaku Co Ltd | ジヒドロピリジン誘導体及びその製法 |
| US4906646A (en) | 1983-03-31 | 1990-03-06 | Board Of Governors Of Wayne State University | Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class |
| US4885284A (en) | 1986-01-22 | 1989-12-05 | Nissan Chemical Industries Ltd. | Dihydropyridine-5-phosphonic acid cyclic propylene ester |
| FR2601366B1 (fr) | 1986-07-10 | 1988-11-25 | Andre Buzas | Derives de la benzhydryloxyethyl-piperazine, procedes d'obtention et de compositions pharmaceutiques les contenant. |
| JP2850376B2 (ja) | 1988-08-02 | 1999-01-27 | 日産化学工業株式会社 | 抗癌剤薬効増強剤 |
| DE68924456T2 (de) | 1988-08-02 | 1996-05-30 | Nissan Chemical Ind Ltd | Mittel zur Verbesserung von Arzneimitteleffekten für Antitumormittel. |
| FR2636946B1 (fr) | 1988-09-23 | 1990-11-02 | Lipha | ((diarylmethoxy)alcoyl)-1 pyrrolidines et piperidines, procedes de preparation et medicaments les contenant |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0467435A3 (en) | 1990-07-19 | 1992-04-01 | Akzo N.V. | Benzhydryl derivatives having calmodulin inhibitor properties |
| GB9020051D0 (en) | 1990-09-13 | 1990-10-24 | Pfizer Ltd | Muscarinic receptor antagonists |
| US5919816A (en) | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US6413967B1 (en) | 1995-03-30 | 2002-07-02 | The University Of Virginia Patents Foundation | Inhibition of novel calcium entry pathway in electrically non-excitable cells acting as an anti-proliferative therapy |
| ATE324114T1 (de) | 1995-09-08 | 2006-05-15 | Beth Israel Hospital | Isolierung der mikrodomänen von kaveolae und gpi verankerten proteinen |
| EP0853615B1 (en) | 1995-09-15 | 2003-12-10 | Neurosearch A/S | Piperidine compounds as calcium channel blockers |
| CN1214688A (zh) | 1996-02-14 | 1999-04-21 | 伊希斯药物有限公司 | 糖修饰的缺口寡核苷酸 |
| CA2204082A1 (en) | 1996-05-03 | 1997-11-03 | Michael William John Urquhart | Pharmaceutical compounds |
| US6191156B1 (en) | 1997-04-11 | 2001-02-20 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating bladder dysfunction |
| US6703374B1 (en) | 1997-10-30 | 2004-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleosides for imaging and treatment applications |
| CA2312195A1 (en) | 1997-12-03 | 1999-06-10 | Merck & Co., Inc. | Low-voltage activated calcium channel compositions and methods |
| WO1999029847A1 (en) | 1997-12-05 | 1999-06-17 | Loyola University Of Chicago | T-type voltage-gated calcium channels and method of using same |
| JPH11246417A (ja) | 1998-03-04 | 1999-09-14 | Nissan Chem Ind Ltd | 糖尿病性腎症治療用医薬組成物 |
| US6372719B1 (en) | 1998-03-04 | 2002-04-16 | Jay Cunningham | ανβ3 integrin antagonists in combination with chemotherapeutic agents |
| JP2002525077A (ja) | 1998-08-26 | 2002-08-13 | サウス、アラバマ、メディカル、サイエンス、ファウンデーション | Ｔ型カルシウムチャンネル |
| US6251886B1 (en) | 1998-12-07 | 2001-06-26 | Schering Corporation | Methods of using temozolomide in the treatment of cancers |
| EP1165508B1 (en) | 1999-04-07 | 2004-06-23 | The University of Virginia Patent Foundation | Anticancer calcium channel blockers |
| US6946475B1 (en) | 1999-04-07 | 2005-09-20 | University Of Virginia Patent Foundation | Anticancer calcium channel blockers |
| US7195783B2 (en) | 1999-07-09 | 2007-03-27 | Fx Life Sciences International Gmbh | Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics |
| AU2001235363A1 (en) | 2000-02-25 | 2001-09-03 | Novo-Nordisk A/S | Mibefradil analogues and their use |
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| DE60127410T2 (de) | 2000-07-27 | 2007-12-13 | Pharmacia Corp. | Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen |
| ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| CA2446806A1 (en) | 2001-05-11 | 2002-11-21 | Board Of Regents, The University Of Texas System | Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 |
| EP1408975A2 (en) | 2001-07-23 | 2004-04-21 | Epidauros Biotechnologie AG | Methods for the treatment of cancer with irinotecan based on cyp3a5 |
| KR101265180B1 (ko) | 2002-01-17 | 2013-05-29 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드, 이를 이용하여 약학적 조성물을 제조하는 방법 및 그 약학적 조성물 |
| CA2486622A1 (en) | 2002-05-20 | 2003-12-04 | Research Development Foundation | Aerosol drug inhibition of lung metastases |
| GB0211578D0 (en) | 2002-05-21 | 2002-06-26 | Univ Belfast | Medicaments |
| DE10227511A1 (de) | 2002-06-19 | 2004-01-08 | Max-Delbrück-Centrum für Molekulare Medizin | Mittel zur medikamentösen Behandlung von akuten und chronischen Schmerzen |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| JP2006502188A (ja) | 2002-09-17 | 2006-01-19 | ニューヨーク ユニバーシティ | 年齢関連記憶欠陥（ａａｍｉ）、中程度認識欠陥（ｍｃｉ）、および痴呆を細胞周期インヒビターで処置する方法 |
| RU2326886C2 (ru) | 2003-03-28 | 2008-06-20 | Ниссан Кемикал Индастриз, Лтд. | Блокатор кальциевых каналов т-типа |
| TW200528107A (en) | 2003-11-25 | 2005-09-01 | Nissan Chemical Ind Ltd | T-type calcium channel inhibitor |
| AU2011203315B8 (en) | 2004-02-11 | 2012-02-16 | University Of Virginia Patent Foundation | Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer |
| EP2319536A1 (en) | 2004-02-11 | 2011-05-11 | University Of Virginia Patent Foundation | Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer |
| CA2555208A1 (en) | 2004-02-18 | 2005-09-01 | Merck & Co., Inc. | Nucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha 1h, encoded proteins and methods of use thereof |
| US20060003020A1 (en) * | 2004-03-11 | 2006-01-05 | The Regents Of The University Of Michigan | Anti-metastatic ability of mibefradil and gadolinium |
| TW200538149A (en) | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
| WO2006003020A1 (en) | 2004-07-02 | 2006-01-12 | L'oreal | Compositions containing a triazine derivative, an arylalkyl benzoate derivative and a eutectic n-butylphthalimide/isopropylphthalimide mixture; cosmetic uses thereof |
| JP4927735B2 (ja) | 2004-08-20 | 2012-05-09 | ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン | Ｔ型カルシウムチャネル阻害剤 |
| JP2008510730A (ja) | 2004-08-20 | 2008-04-10 | ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン | Ｔ型カルシウムチャネルブロッカーおよび疾患の治療 |
| US20100222406A1 (en) | 2007-09-11 | 2010-09-02 | University Of Virginia Patent Foundation | T Type Calcium Channel Blockers and the Treatment of Diseases |
| US20120264804A1 (en) | 2004-08-20 | 2012-10-18 | University Of Virginia Patent Foundation | T type calcium channel blockers and the treatment of diseases |
| US7851431B2 (en) | 2005-07-27 | 2010-12-14 | Prescription Dispensing Laboratories | Treatment of actinic keratoses with calcium channel blockers |
| KR100743255B1 (ko) | 2006-05-04 | 2007-07-27 | 한국과학기술연구원 | Ｔ-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체 |
| CA2660438A1 (en) * | 2006-08-10 | 2008-02-14 | Oncotherapy Science, Inc. | Genes and polypeptides relating to breast cancers |
| CN101528768A (zh) * | 2006-08-10 | 2009-09-09 | 肿瘤疗法科学股份有限公司 | 与乳腺癌相关的基因和多肽 |
| KR20140148491A (ko) | 2006-12-19 | 2014-12-31 | 제넨테크, 인크. | 조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 ｖｅｇｆ－특이적 길항제 |
| CA2684938A1 (en) | 2007-05-02 | 2008-11-13 | Tau Therapeutics Llc | Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions |
| WO2008141189A1 (en) | 2007-05-09 | 2008-11-20 | Elixir Pharmaceuticals, Inc. | Ghrelin modulating compounds and combinations thereof |
| EP2190429B1 (en) | 2007-09-10 | 2016-04-20 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| JP5029328B2 (ja) | 2007-12-05 | 2012-09-19 | マツダ株式会社 | 自動車の前部車体構造 |
| MX2010012064A (es) | 2008-05-05 | 2010-12-06 | Schering Corp | Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer. |
| MX2011000233A (es) | 2008-07-08 | 2011-05-19 | Oncomed Pharm Inc | Agentes de union del receptor notch1 y metodos para su uso. |
| KR101905050B1 (ko) | 2009-06-05 | 2018-10-08 | 타우 쎄라퓨틱스 엘엘씨 | 암 또는 전암성 질환을 치료하기 위한 인터레이스 방법 |
| AU2011223883B2 (en) | 2010-03-01 | 2015-10-08 | Cavion, Inc. | Cancer diagnosis and imaging |
| EP2755674A4 (en) | 2011-09-12 | 2015-04-08 | Tau Therapeutics Llc | ANTAGONISTS OF PRODUCTS OF THE HS-459642-UNIGEN CLUSTER TO AVOID PROLIFERATION, DEVELOPMENT, OR DIFFERENTIATION OF STEM CELLS WITH CANCER STEM CELLS |
-
2011
- 2011-02-28 AU AU2011223883A patent/AU2011223883B2/en not_active Ceased
- 2011-02-28 ES ES11751125.3T patent/ES2557407T3/es active Active
- 2011-02-28 JP JP2012556123A patent/JP6017964B2/ja not_active Expired - Fee Related
- 2011-02-28 CA CA2787673A patent/CA2787673A1/en not_active Abandoned
- 2011-02-28 WO PCT/US2011/026416 patent/WO2011109262A2/en not_active Ceased
- 2011-02-28 US US13/581,390 patent/US9427429B2/en not_active Expired - Fee Related
- 2011-02-28 EP EP11751125.3A patent/EP2542155B1/en not_active Not-in-force
- 2011-02-28 CN CN201180011495.2A patent/CN102781316B/zh not_active Expired - Fee Related
- 2011-02-28 SG SG10201501496TA patent/SG10201501496TA/en unknown
- 2011-02-28 KR KR1020127022975A patent/KR101821343B1/ko not_active Expired - Fee Related
- 2011-02-28 SG SG2012055232A patent/SG183114A1/en unknown
- 2011-02-28 MX MX2012010119A patent/MX360640B/es active IP Right Grant
-
2012
- 2012-07-18 ZA ZA2012/05377A patent/ZA201205377B/en unknown
- 2012-07-19 IL IL221035A patent/IL221035A0/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201205377B (en) | 2013-09-25 |
| WO2011109262A3 (en) | 2011-11-17 |
| WO2011109262A2 (en) | 2011-09-09 |
| ES2557407T3 (es) | 2016-01-25 |
| EP2542155B1 (en) | 2015-11-04 |
| CA2787673A1 (en) | 2011-09-09 |
| HK1179143A1 (zh) | 2013-09-27 |
| AU2011223883A1 (en) | 2012-09-13 |
| US9427429B2 (en) | 2016-08-30 |
| CN102781316B (zh) | 2016-07-06 |
| SG183114A1 (en) | 2012-09-27 |
| US20120321561A1 (en) | 2012-12-20 |
| CN102781316A (zh) | 2012-11-14 |
| KR101821343B1 (ko) | 2018-01-23 |
| KR20130014506A (ko) | 2013-02-07 |
| MX360640B (es) | 2018-11-09 |
| MX2012010119A (es) | 2012-09-12 |
| AU2011223883B2 (en) | 2015-10-08 |
| EP2542155A2 (en) | 2013-01-09 |
| JP6017964B2 (ja) | 2016-11-02 |
| EP2542155A4 (en) | 2013-07-17 |
| IL221035A0 (en) | 2012-09-24 |
| JP2013521287A (ja) | 2013-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL221035A0 (en) | Cancer diagnosis and imaging | |
| EP2687144A4 (en) | IMAGING UNIT AND ENDOSCOPE | |
| GB2478329B (en) | Medical image processing | |
| EP2575602A4 (en) | MEDICAL IMAGING SYSTEM AND ASSOCIATED METHODS | |
| EP2614773A4 (en) | IMAGING DEVICE FOR X-RAY GENTOMOGRAMS | |
| PT2829881T (pt) | Diagnóstico para cancro colo-rectal | |
| EP2604176A4 (en) | IMAGING DEVICE | |
| EP2531105A4 (en) | RADIATION IMAGING SYSTEM | |
| EP2629504A4 (en) | IMAGING DEVICE | |
| EP2563225A4 (en) | PHOTOACUSTIC CONVERTER AND IMAGING SYSTEM | |
| GB0922085D0 (en) | Cancer diagnosis and treatment | |
| HRP20181726T1 (hr) | Neinvazivno dijagnosticiranje raka | |
| IL225404A0 (en) | 3D imaging | |
| GB2482066B (en) | Imaging | |
| EP2567211A4 (en) | DIAGNOSTIC SYSTEM AND COMPONENTS | |
| GB201008541D0 (en) | Diagnostic methods | |
| PT2646980T (pt) | Técnica de imagiologia e sistema de imagiologia | |
| PT2628146T (pt) | Nova modalidade de imagem usando radiações penetrantes | |
| IL220972B (en) | High resolution imaging radar | |
| EP2541281A4 (en) | Radiological imaging device | |
| GB201016411D0 (en) | In vivo imaging method for cancer | |
| GB2496530B (en) | Three-dimensional imaging | |
| GB0901837D0 (en) | Cancer diagnosis and treatment | |
| ZA201304156B (en) | Imaging agents | |
| GB201012209D0 (en) | In vivo imaging agent |